Shilpa Medicare Invests $2M in US Biotech Alveolus Bio to Advance Lung Disease Therapies

Shilpa Medicare Limited, a leading Indian pharmaceutical company, has announced a strategic investment of $2 million in US-based Alveolus Bio, Inc. The investment will fund Alveolus Bio’s lead COPD program through Phase 2 clinical trials and accelerate additional preclinical programs. Shilpa Biologics Private Limited, the biologics arm of Shilpa Medicare, will serve as the exclusive global development and manufacturing partner for Alveolus Bio. This collaboration aims to leverage Shilpa’s expertise in turnkey biologics development, process optimization, and manufacturing with Alveolus Bio’s cutting-edge resMIT platform.